Papers
7
Total Citations
202
H-Index
5
About
Matthijs J. Scheltema is a leading urologic oncologist whose research centers on advancing prostate cancer treatment through robotic surgery, focal therapy, and molecular imaging. His landmark study on robotic radical prostatectomy, analyzing over 2,200 consecutive cases, demonstrated that superior biochemical recurrence rates and long-term quality-of-life outcomes are achievable after a prolonged learning curve—a finding with 75 citations that has shaped surgical practice. Scheltema pioneered robot-assisted PSMA-radioguided surgery, a technique using radioactive tracers to detect lymph node metastases during prostatectomy, with a 51-cited feasibility study. He has been instrumental in evaluating focal irreversible electroporation (IRE) as a less invasive alternative, showing in a 40-cited pair-matched study that IRE offers favorable quality-of-life preservation compared to radical prostatectomy. His work on salvage robotic prostatectomy after failed IRE (16 citations) and the IRE-IMMUNO study (13 citations), which revealed that IRE can downregulate immune suppression and induce systemic anti-tumor T-cell activation, highlight his contributions to both oncologic control and immunotherapy. Scheltema’s research continues to refine risk stratification using PSMA PET/CT, demonstrating its prognostic value in predicting biochemical recurrence. His integrated approach—combining surgical innovation, focal therapy, and molecular imaging—positions him at the forefront of personalized prostate cancer management.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4
- 5
- 6
- 7